Aldoro Resources set to start its maiden drilling program

|

Published 14-MAY-2021 12:11 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Aldoro Resources (ASX:ARN) is set to begin its maiden drilling campaign.

ARN has 100% of the Narndee Nickel PGE Project in WA and has now secured its diamond drilling contractor - expected to be on site in June.

The company is chasing a Chalice Mines style discovery.

Chalice Mines discovered the world class Julimar PGE-Ni-Cu-Co-Au discovery in WA in 2020. This was Australia’s first major palladium discovery and opened up an entirely new minerals province.

Chalice went from 20c to $5.31 - that’s over 25 x return. It is now capped at $2.6BN...

The $26.9M capped Aldoro will begin with a 5000 metre program and has the ability to increase its program as results come in.

The drilling announcement comes just a month after ARN completed its Fixed Loop Electromagnetic (FLTEM) survey at the group’s Narndee Project in Western Australia.

The FLTEM data’s initial processing confidently constrained two walk-up, drill-ready targets, being VC1 and VC11.

Drilling will focus on confirmed high confidence anomalies VC1, VC11 and VC8.

These holes will also be assessed to determine their viability to conduct DHTEM surveys.

Those surveys will then be used to assess the size and nature of the in-hole bedrock conductors at depth, and also identify adjacent, off-hole bedrock conductors.

Aldoro is in the process of finalising a gradient array (GAIP) survey - an electrical geophysical technique which has the ability to identify disseminated sulphide mineralisation.

This type of survey helps de-risk the Project and refine its targets.

ARN will further investigate the use of a GAIP survey over all 11 high-interest anomalies (VC1-VC11) identified from the FLTEM survey.

ARN is backed internationally renowned geologist Dr Minlu Fu, who invested $2M into the company making his entity Dr Minlu Fu and Associates one of ARN’s largest shareholders.

Dr Fu’s previous successes and enviable track record involve a number of nickel, copper and gold discoveries and it is the potential to make a large nickel discovery that attracted him to make a strategic investment in ARN.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X